Cookson Peirce & Co’s Corcept Therapeutics CORT Stock Holding History

Cookson Peirce & Co’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-207,457	Closed	-$7.22M	–	314
2025 Q4	$7.22M	Sell	207,457 -3,848	-2%	-$302K	0.3%	75
2025 Q3	$17.6M	Sell	211,305 -6,117	-3%	-$443K	0.72%	45
2025 Q2	$16M	Sell	217,422 -18,397	-8%	-$1.33M	0.7%	46
2025 Q1	$26.9M	Buy	235,819 +199,216	+544%	+$12.1M	1.35%	26
2024 Q4	$1.84M	Buy	+36,603	New	+$1.92M	0.08%	95

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cookson Peirce & Co's CORT Position: Q1 2026 in Review

Cookson Peirce & Co sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 207,457 shares — an estimated $7.22M sold.

Cookson Peirce & Co first reported a position in CORT in Q4 2024 and held it in 5 quarters. The position peaked at $26.9M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Cookson Peirce & Co reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Cookson Peirce & Co sold 207,457 Corcept Therapeutics shares in Q1 2026, an estimated $7.22M.
Cookson Peirce & Co first reported a position in Corcept Therapeutics in Q4 2024 and held it in 5 quarters.
Cookson Peirce & Co's Corcept Therapeutics position peaked at $26.9M in Q1 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Cookson Peirce & Co's 13F filing for Q1 2026, filed 30 Apr 2026.